That conclusion is additionally supported by previously published evidence that low activity of MBL-MASP-2 complexes (strongly correlating with MBL concentration and MBL-MASP-1 activity) offer protection against LCOS, SIRS, renal insufficiency and multi-organ failure5,6. The gene discussed is MBL2; the disease is systemic inflammatory response syndrome.